These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
158 related items for PubMed ID: 18396651
1. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. Hui R, Zhang M, Hao XM, Zhang J. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651 [Abstract] [Full Text] [Related]
7. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. J Clin Oncol; 2012 Jan 01; 30(1):11-8. PubMed ID: 22105826 [Abstract] [Full Text] [Related]
8. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I. J Clin Oncol; 2004 Aug 01; 22(15):3070-9. PubMed ID: 15284257 [Abstract] [Full Text] [Related]
9. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer]. Yang D, Tong F, Cao Y, Liu P, Zhou B, Liu H, Qiao X, Zhang J. Zhonghua Zhong Liu Za Zhi; 2002 May 01; 24(3):303-5. PubMed ID: 12515634 [Abstract] [Full Text] [Related]